by RANDY ROWE | Aug 10, 2021
The past year has been a “reckoning” for the Canadian cannabis sector. Many cannabis companies remain unable to turn a profit; but that’s almost a success story compared to those struggling to make payroll and in some cases, even survive. Against this backdrop there are also success stories. The truth is, some cannabis companies have adapted and are finding a way to succeed.
This panel will bring together a group of people who understand the many challenges faced by cannabis companies and have unique insights into what it takes to succeed in Canadian cannabis. We will discuss what went wrong but more importantly, we will focus on what smart cannabis companies should be doing now to turn things around for sustainable success.
Moderator – David Hyde
by RANDY ROWE | Aug 10, 2021
by RANDY ROWE | Aug 10, 2021
A tour de force of psilocybe mushrooms from historical use, legal status, growth cycles, understanding chemical makeup, and how psilocybin affects the brain and body.
by RANDY ROWE | Aug 10, 2021
Bruce Linton may forever be known for jumpstarting the Canadian cannabis industry as CEO of Canopy Growth. Or that may simply be known as his first home run. His next opportunity, Gage Cannabis, led the charge into the slowly loosening U.S. market via Michigan, with 19 “Class C” cultivation licenses, 15 dispensaries, and three processing licenses. And now, Gage has become a bigger player with the company’s all-stock $545 million purchase by TerrAscend. Bruce has graced us with his presence before, each time with some new venture percolating. In this keynote address, expect some hints of things to come.
Interviewer – Samantha Roman
by RANDY ROWE | Aug 10, 2021
There are big growers and there are micro-cultivators. And as strange as it may seem, there are more hoops to jump through and licenses to pay for if you decide to grow the cannabis equivalent of a craft beer. With processor licenses, sales licenses, nursery licenses and harvest limits, experts say a start-up could cost anywhere from $250k to $2 million. And yet, as consumer connoisseurship grows, and the willingness to pay for quality follows, micro-cultivators may be ideally suited to experiment with and grow higher-quality strains. This panel will examine the potential profit of limited-edition cannabis growing versus the cost.
Moderator – Dr. Av Singh
by RANDY ROWE | Aug 10, 2021
Truly a global phenomenon, cannabis is finding devotees in all its incarnations, from recreational to hemp to medicinal (Israel, for example, recently passed Germany as the largest importer of medicinal flowers). There is practically no place in the world where demand does not tempt investors. At the same time, there are many countries that still outlaw the drug. And COVID-19 has created its own foreign investment barriers, from restrictions on retail and travel to supply chain disruptions. Various market research studies have tried to make sense out of the emerging international market. This session will tell you what we know, what we don’t know, and what the profit potential is from Africa to Asia to Europe to South America.
Moderator – Matt Lamers
by RANDY ROWE | Aug 10, 2021
In a pandemic-stricken global economy, there is every reason to expect the worst. But despite what many consider high and/or unfair taxes, regulatory handcuffs and crippled supply chains, the durability of the cannabis industry has surprised many. In a research report from Prospiant and Cannabis Business Times, 31% of participants reported increased revenues in 2020 and 73% planned to imminently add cultivation space (indoor, outdoor or greenhouse). Is it overly optimistic to expect these trends to continue, or does this suggest better things to come? We’ll assess our industry’s strengths and its ability to endure.
Moderator – Terry Roycroft
by RANDY ROWE | Aug 10, 2021
Cannabis Industry Veteran, USA healthcare industry expert, Social Media Influencer, and Podcast host Michael Patterson sits down with Samantha Roman to discuss current industry trends, International trade, ancillary businesses opportunities related to cannabis, the cannabis global value chain, cannabis education, and much more!
Michael Patterson is the CEO of US Cannabis Pharmaceutical Research and Development, which focuses on moving society forward through legalized cannabis. US Cannabis develops the legal cannabis/hemp/cbd industry across multiple platforms (cultivation, processing, dispensing, trade, education, regulation/law, licensing, payments, compliance). Mr. Patterson is also President of MGMC Pharma Group (International Pharmaceutical company focusing on vaccine development and cannabis products), Advisory Board member for Akers Bio (NASDAQ listed company), Editorial Board member for AJEM-American Journal of Endocannabinoid Medicine (world’s first peer reviewed, printed journal dedicated to the study of the endocannabinoid science), Advisory Board member for ICS- Integrated Compliance Solutions (largest merchant processor for THC and hemp/cbd related businesses in the USA), and Podcast host of “The Cannabis Report with Michael Patterson”.
Moderator – Samantha Roman
by RANDY ROWE | Aug 10, 2021
by RANDY ROWE | Jul 26, 2021
Industry analysts are bullish about the financial potential of the psychedelic drug market, predicting North American sales of almost $7 billion by 2027. A continuing search for new and effective treatments for burgeoning mental illnesses fuels the confidence. On the other hand, new medicinal drugs can face more regulatory roadblocks than recreational ones. This panel, representing some of the most active companies in psychedelic research and development, will come up with a realistic timetable for the full greenlight for licensed psychoactive healing.
Moderator – Katie Pringle
Recent Comments